Navigation Links
HIV Patients Opposes Patenting Of AIDS Drug

An Indian group of people living with HIV/AIDS have opposed a patent application filed by global pharma major GlaxoSmithKline for Combivir, a fixed dose combination AIDS drug on the grounds that it would make the treatment unaffordable. //

Represented by the Lawyers' Collective HIV/AIDS Unit, the Indian Network of People Living with HIV/AIDS and the Manipur Network of Positive People Thursday officially submitted their opposition to a patent application filed at the Kolkata patent office by GlaxoSmithKline.

The opposition is based on technical and health grounds.

'We are objecting to the patenting of Combivir - a fixed-dose combination of the two essential AIDS drugs zidovudine and lamivudine - because it is not a new invention but simply the combination of two existing drugs,' said K.K. Abraham, president of the Indian Network of People Living with HIV/AIDS.

'More importantly, the granting of such a patent risks increasing the cost of anti-retroviral treatment for many people living with HIV/AIDS, thereby further increasing the burden on developing countries already struggling to treat patients.'

Combivir is used extensively in projects run by international aid organisations such as Medecins Sans Frontieres (MSF). Almost all the Combivir used by MSF is generic.

India, Burkina Faso, Mongolia, Central African Republic, Malawi, Peru, Kyrgyzstan, Cambodia, Ukraine and Swaziland are other countries identified by the Global Fund for using generic Combivir.

'Decisions made by Indian patent offices are a question of life or death for people living with HIV/AIDS who rely on the availability of affordable AIDS drugs and other essential medicines made by Indian generic manufacturers,' said Anand Grover, director of Lawyers Collective HIV/AIDS Unit.

Last year, India changed its patent law to comply with the World Trade Organisation's TRIPS Agreement that governs trade pacts and in tellectual property rights.

Three weeks ago, India granted its first patent on a drug to a Hepatitis C treatment produced by Roche.

Public interest groups are deeply concerned that this will set a precedent, leading to the patenting of other essential medicines including anti-retrovirals for treatment of HIV/AIDS.

--Edited IANS
'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... ... 22, 2017 , ... ANGLESTRONG , the new recovery management app with ... App Store and Google Play . Florida-based Sober Network, Inc., the ... industry, partnered with Angle to build ANGLESTRONG. The new recovery management app is a ...
(Date:2/22/2017)... ... February 22, 2017 , ... A product of digesting a ... derive a heart-protective benefit from eating soy foods, while others do not, a University ... are able to produce equol—a substance made by some types of “good” gut bacteria ...
(Date:2/22/2017)... ... 2017 , ... Super-Sod will attend the Athens Home Show with a brand ... shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit space ... manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm in ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a home ... University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, March ... Aging is a tremendous resource in our community. We are thrilled to participate in ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a leading global ... management, today announced that Keppel Corporation has selected Apptricity Travel and Expense Management ... “We are excited to announce the partnership between Keppel and Apptricity for our ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... fiscal year ended December 31, 2016. ... This news release should ... and management discussion and analysis for the years ended December ... and are available at www.sedar.com and on the ...
(Date:2/22/2017)... Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... 2016 investor conference call and webcast at 8:30 a.m., Eastern ... will cover an update on Merrimack,s recent progress as well ... financial results. A press release detailing the information to be ... Wednesday, March 1. Investors and the general public are invited ...
(Date:2/22/2017)... 2017 Summary Provides understanding and ... and agreements entered into by the worlds leading healthcare ... Description The Global Non-Small Cell Lung Cancer Partnering ... access to partnering deals and agreements entered into by ... in partnering deals - Top deals by value ...
Breaking Medicine Technology: